东亚药业: 东亚药业2025年半年度业绩预告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. expects a significant decline in net profit for the first half of 2025, projecting a loss between 28 million to 35 million yuan, compared to a profit of 32.47 million yuan in the same period last year [1][2]. Performance Forecast - The company anticipates a net profit attributable to shareholders of the listed company to be between -28 million yuan and -35 million yuan for the first half of 2025 [1]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -33 million yuan and -40 million yuan [1]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders was 32.47 million yuan, with a net profit of 26.93 million yuan after deducting non-recurring gains and losses [2]. - The earnings per share for the previous year was 0.29 yuan [2]. Reasons for Performance Decline - The decline in net profit is attributed to several factors: - Revenue Side: The company faced reduced demand for some products due to global economic slowdown, industry-related policies, and intensified competition, leading to a decrease in gross profit by approximately 30 million yuan [2]. - Asset Side: The company plans to make impairment provisions for certain assets, including inventory, due to expected realizable net values being lower than costs [2]. - Despite these challenges, the company is committed to its integrated development strategy for raw materials and formulations, aiming to enhance product lines and maintain market share [2]. Strategic Outlook - The management expresses confidence in the company's future operational development, focusing on cost reduction, organizational transformation, and improving operational quality to enhance product competitiveness and efficiency [2].